Announcement PDF ASX RELEASE 28 August 2025 InvestorHub Portal Launch Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to advise that it has launched ‘InvestorHub’, a new initiative dedicated to engaging with shareholders and market participants. InvestorHub will provide shareholders and interested parties with convenient access to the Company’s ASX announcements, shareholder news, and key updates, all in one place. Paradigm is entering a pivotal period as it advances its pivotal Phase 3 clinical trial (PARA_OA_012) evaluating injectable pentosan polysulfate sodium (iPPS/Zilosul®) for the treatment of pain associated with knee osteoarthritis. Key near-term value drivers over the next 12 months include: • Ongoing site activations and patient dosing across the US and Australia, • Achieving 25%, 50%, 75% and ultimately 100% participant recruitment in PARA_OA_012, and • Delivery of an interim analysis at the 50% recruitment milestone. The Company expects to regularly upload new content to InvestorHub, including videos, trial progress updates, and other relevant news for the market. Shareholders and interested market participants are invited to sign up to the platform via the link below. InvestorHub also enables investors to ask questions and provide feedback through its Q&A function, creating a forum for direct engagement with Paradigm’s leadership team. Paradigm Managing Director, Mr Paul Rennie, said: “Paradigm is pleased to launch InvestorHub as a central platform for our shareholders to follow the progress of our pivotal Phase 3 program. With recruitment milestones and the interim analysis ahead, 2025 and 2026 represent a transformational period for the Company. InvestorHub allows us to share these important developments directly with our shareholders as we advance this global study.” Watch Mr Rennie’s introduction to the new InvestorHub portal here: https://investors.paradigmbiopharma.com/link/y05pBe To view the Company’s InvestorHub, please visit: https://investors.paradigmbiopharma.com -Ends- About Paradigm Biopharmaceuticals Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3). To learn more please visit: https://paradigmbiopharma.com Approved for release by the Paradigm Board of Directors. FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email: investorrelations@paradigmbiopharma.com